Skip to main content

A Trial to Evaluate an HIV Vaccine, N332-GT5 gp140, in Adult Participants Without HIV

Research Question:
Is the vaccine, N322-GT5 gp140 safe in adults without HIV and does it induce an immune response?

Basic Study Information

Finding a vaccine against HIV remains a top priority for public health. This study, called HVTN 144, is an early step in the process. It's like testing the first pieces of a puzzle before building the whole picture. The goal is to see if a new HIV vaccine candidate is safe and can trigger the right immune response in people without HIV. The vaccine candidate itself is a protein called N332-GT5 gp140, combined with a special booster called SMNP. The study will involve two parts: Part 1: 84 healthy adults between 18 and 55 years old will receive the vaccine candidate at different doses and schedules. This helps find the safest and most effective way to give the vaccine. Part 2: The best dose and schedule from Part 1 will be used to see how well the vaccine triggers the desired immune response, specifically a certain type of antibody called BG18-class IgG. The whole study will take about 22 months. Most of that time is for safety monitoring and follow-up after the last vaccination.

Location: University of Rochester Medical Center
Study Reference #: STUDY00008618

Lead Researcher (Principal Investigator)

Lead Researcher:  Michael Keefer

Study Contact Information

Study Coordinator: Michael Keefer, MD
Phone: (585) 275-5871

Additional Study Details

Reimbursement:  Yes

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search